Circulation patterns and molecular epidemiology of human respiratory syncytial virus over five consecutive seasons in Morocco.
Morocco
circulation patterns
genotype
phylogenetic analysis
respiratory syncytial virus
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
04
05
2023
revised:
05
09
2023
accepted:
10
09
2023
medline:
23
10
2023
pubmed:
20
10
2023
entrez:
20
10
2023
Statut:
epublish
Résumé
Respiratory syncytial virus (HRSV) is the leading cause of respiratory tract infections in infants and young children. we investigated the prevalence and characteristics of HRSV in Morocco and explored trends in circulating genotypes through partial G gene analysis of HRSV strains prevalent from 2012 to 2017. Respiratory samples were gathered from both outpatients and inpatients meeting ILI or SARI case definitions. The patients' ages varied from 1 month to 99 years old. Nucleic acids were extracted and HRSV type/subtype was detected by RT-qPCR. A subset of positive samples was randomly selected in each epidemic year, the complete viral genome was sequenced, phylogenetic analysis was performed using the MEGA7 program and the genotypes were confirmed. The 3679 specimens were collected from 2012 to 2017, of which 726 (19.7%) were positive for HRSV. The 35% (257/726) of HRSV-positives were of the HRSV-A subtype, while the HRSV-B subtype accounted for 61% (442/726). The co-infection rate was 3.7% (27/726). The virus circulates in a periodic pattern, where epidemics occur during the fall months through early spring. HRSV genotype was confirmed in 127 specimens (56 HRSV-A and 71 HRSV-B). Based on phylogenetic analysis, all HRSV-A were ON1 genotype, and HRSV-B were mostly BA9 genotype. HRSV-B belonging to the BA10 genotype was detected in 2012 exclusively. BA9, BA10, and ON1 were the only HRSV genotypes detected between 2012 and 2017. Variations in the G gene amino acid chain were identified in local strains, which suggests an increased need for continuous genomic surveillance.
Sections du résumé
Background
Respiratory syncytial virus (HRSV) is the leading cause of respiratory tract infections in infants and young children. we investigated the prevalence and characteristics of HRSV in Morocco and explored trends in circulating genotypes through partial G gene analysis of HRSV strains prevalent from 2012 to 2017.
Methods
Respiratory samples were gathered from both outpatients and inpatients meeting ILI or SARI case definitions. The patients' ages varied from 1 month to 99 years old. Nucleic acids were extracted and HRSV type/subtype was detected by RT-qPCR. A subset of positive samples was randomly selected in each epidemic year, the complete viral genome was sequenced, phylogenetic analysis was performed using the MEGA7 program and the genotypes were confirmed.
Results
The 3679 specimens were collected from 2012 to 2017, of which 726 (19.7%) were positive for HRSV. The 35% (257/726) of HRSV-positives were of the HRSV-A subtype, while the HRSV-B subtype accounted for 61% (442/726). The co-infection rate was 3.7% (27/726). The virus circulates in a periodic pattern, where epidemics occur during the fall months through early spring. HRSV genotype was confirmed in 127 specimens (56 HRSV-A and 71 HRSV-B). Based on phylogenetic analysis, all HRSV-A were ON1 genotype, and HRSV-B were mostly BA9 genotype. HRSV-B belonging to the BA10 genotype was detected in 2012 exclusively.
Conclusions
BA9, BA10, and ON1 were the only HRSV genotypes detected between 2012 and 2017. Variations in the G gene amino acid chain were identified in local strains, which suggests an increased need for continuous genomic surveillance.
Identifiants
pubmed: 37859975
doi: 10.1111/irv.13203
pii: IRV13203
pmc: PMC10582604
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13203Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NCPDCID CDC HHS
ID : U51 CI000469
Pays : United States
Informations de copyright
© 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Clin Vaccine Immunol. 2016 Jan 27;23(3):186-8
pubmed: 26818954
Virol J. 2018 Jul 18;15(1):109
pubmed: 30021648
Microbiol Spectr. 2023 Aug 17;11(4):e0260622
pubmed: 37409937
PLoS One. 2014 Oct 07;9(10):e109191
pubmed: 25290155
Rev Med Virol. 2001 Mar-Apr;11(2):103-16
pubmed: 11262529
Emerg Infect Dis. 2017 Feb;23(2):264-271
pubmed: 28098528
N Engl J Med. 2001 Jun 21;344(25):1917-28
pubmed: 11419430
PLoS One. 2018 Jan 29;13(1):e0192085
pubmed: 29377949
Lancet. 2010 May 1;375(9725):1545-55
pubmed: 20399493
Influenza Other Respir Viruses. 2020 Nov;14(6):647-657
pubmed: 31670892
Epidemiol Infect. 2007 Oct;135(7):1099-108
pubmed: 17291381
J Clin Virol. 2018 May;102:12-18
pubmed: 29471266
Emerg Infect Dis. 2021 Jun;27(6):1-9
pubmed: 34013862
Antiviral Res. 2004 Mar;61(3):165-71
pubmed: 15168797
J Virol. 2010 Aug;84(15):7500-12
pubmed: 20504933
East Mediterr Health J. 2016 Oct 02;22(7):483-490
pubmed: 27714743
PLoS One. 2013 Sep 13;8(9):e74018
pubmed: 24058513
Nucleic Acids Res. 2010 Jan;38(Database issue):D46-51
pubmed: 19910366
J Glob Health. 2015 Dec;5(2):010419
pubmed: 26649172
Infection. 2003 Mar;31(2):75-80
pubmed: 12682811
J Infect. 2022 Feb;84(2):216-226
pubmed: 34953903
J Clin Microbiol. 2010 Sep;48(9):3423-7
pubmed: 20610675
Int J Infect Dis. 2020 Jan;90:5-17
pubmed: 31634614
PLoS One. 2011;6(9):e24579
pubmed: 21931764
J Gen Virol. 1997 Oct;78 ( Pt 10):2411-8
pubmed: 9349459
J Virol. 2004 May;78(9):4675-83
pubmed: 15078950
Pac Symp Biocomput. 2002;:310-22
pubmed: 11928486
PLoS Pathog. 2009 Jan;5(1):e1000254
pubmed: 19119418
Epidemiol Infect. 2005 Apr;133(2):279-89
pubmed: 15816153
Microorganisms. 2020 May 11;8(5):
pubmed: 32403364
Bull World Health Organ. 2018 Feb 1;96(2):122-128
pubmed: 29403115
PLoS One. 2016 Jun 17;11(6):e0157163
pubmed: 27315120
PLoS One. 2021 May 18;16(5):e0251361
pubmed: 34003843
J Infect Dis. 2000 Jun;181(6):1891-6
pubmed: 10837167
J Virol Methods. 2012 Dec;186(1-2):189-92
pubmed: 22796284
PLoS One. 2018 Sep 10;13(9):e0203788
pubmed: 30199549
J Infect Dis. 1991 Mar;163(3):464-9
pubmed: 1995719
PLoS One. 2012;7(3):e32807
pubmed: 22470426
J Gen Virol. 2003 Nov;84(Pt 11):3115-3120
pubmed: 14573817
J Clin Microbiol. 2009 Aug;47(8):2475-82
pubmed: 19553576
EMBO J. 2013 May 15;32(10):1478-88
pubmed: 23584533
Clin Microbiol Rev. 2017 Jan;30(1):277-319
pubmed: 27903593
Emerg Infect Dis. 2014 Jun;20(6):950-9
pubmed: 24856417
Emerg Infect Dis. 2022 Mar;28(3):764
pubmed: 35202531